 LEXINGTON, Mass., Dec. 21, 2022 GLOBE NEWSWIRE -- Agenus Inc. NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in combination with balstilimab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium ASCO-GI, to be held January 19-21, 2023, in San Francisco, CA. 